Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, María Trojano, Mattia Fonderico et al.|Brain|2020Cited by 90
Multiple Sclerosis Progression and Relapse Activity in ChildrenPietro Iaffaldano, Roberto Bombardi, Emilio Portaccio et al.|JAMA Neurology|2023Cited by 44
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factorsPietro Iaffaldano, Giuseppe Lucisano, Francesco Patti et al.|Multiple Sclerosis Journal|2020Cited by 32
Genome-Wide Analyses Identify KIF5A as a Novel ALS GeneAude Nicolas, R Myers, Wouter van Rheenen et al.|SSRN Electronic Journal|2018Cited by 32
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple SclerosisEmilio Portaccio, Nicola Renato Pizio, Mattia Fonderico et al.|JAMA Neurology|2022Cited by 17